• S N Avdeev, O A Volkova, I V Demko, G L Ignatova, I V Leshchenko, N A Kanukova, L M Kudelya, V A Nevzorova, N G Nedashkovskaya, O P Ukhanova, L V Shulzhenko, and R S Fassakhov.
• Sechenov First Moscow State Medical University (Sechenov University).
• Terapevt Arkh. 2020 Apr 27; 92 (2): 119-123.

AbstractThe meeting of the Expert board was held in Moscow on June 24, 2019, at which the following issues were considered: the applicability of a new terminology characterizing asthma endotypes and phenotypes in real clinical practice, the effect of phenotypes and biomarkers in patients with bronchial asthma on the choice of biological drug, as well as the optimal clinical profiles of patients for whom dupilumab is most effective, taking into account the data of the III phase clinical trials, regional features of medical care and changes in updated international clinical guidelines for the diagnosis and treatment of asthma. The Expert board included members of leading Russian scientific and educational medical institutions: S.N. Avdeev, corresponding member of the Russian Academy of Sciences, prof., MD; O.A. Volkova, Ph.D.; I.V. Demko, prof., MD; G.L. Ignatova, prof., MD; I.V. Leshchenko, prof., MD; Kanukova N.A.; Kudelya L.M., prof., MD; V.A. Nevzorova, prof., MD; N.G. Nedashkovskaya; O.P. Ukhanova, prof., MD; L.V. Shulzhenko, prof., MD; R.S. Fassakhov, prof., MD.

16 keywords...

hide…